Is Your Alcohol Sanitizer Safe and Effective? Chula’s Pharmaceutical Science Has Developed a User-friendly and Rapid Test Kit to Keep People Away from COVID-19.

Chula Pharmaceutical Science helps increase public confidence to keep COVID-19 at bay with their new test kit to verify the safety and efficacy of hand sanitizers and alcohol-based gel and spray products.

Rural Bangladeshis turn to faith, family for fact-checking

On top of the COVID-19 pandemic, people worldwide have dealt with an infodemic – a flood of ever-evolving information and misinformation about the virus, causing confusion and mistrust. New Cornell research finds that in remote parts of Bangladesh with little internet access, people have relied on local experts, spiritual views and their sense of social justice to evaluate new coronavirus information.

Yale researchers develop RNA-based therapy that clears SARS-CoV-2 from mice

Researchers at Yale School of Medicine have discovered that an RNA molecule that stimulates the body’s early antiviral defense system can protect mice from a range of emerging SARS-CoV-2 variants. The study, published today in the Journal of Experimental Medicine (JEM), could lead to new treatments for COVID-19 in immunocompromised patients, as well as providing an inexpensive therapeutic option for developing countries that currently lack access to vaccines.

Genome sequencing reveals widespread COVID-19 infection in white-tailed deer

Houston Methodist’s SARS-CoV-2 genome sequencing team has partnered on a study led by Penn State that revealed 80% of white-tailed deer sampled across Iowa at the height of the 2020-2021 deer-hunting season tested positive for the SARS-CoV-2 virus. Analysis of the virus genome sequences revealed infections were likely the result of multiple human-to-deer transmission “spillover” events followed by deer-to-deer transmission from April 2020 through January 2021.

Expert Alert: 5 ways patients who are immunocompromised can protect themselves from COVID-19

As families prepare to gather later this month for Thanksgiving, it is important for patients who are immunocompromised to take extra steps to protect themselves from becoming infected with COVID-19. People who are immunocompromised have weakened immune systems, which means they have a higher risk of becoming severely ill from COVID-19.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Launch State’s First Home Infusion Program

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have partnered with Horizon Blue Cross Blue Shield of New Jersey to launch a collaborative pilot program which provides oncology care to eligible patients in the comfort of their own home – the first of its kind in the state.

Study Is First to Examine Fibrocyte Levels in People Hospitalized with COVID-19 Pneumonia

Article title: Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia Authors: Mada Ghanem, Méline Homps-Legrand, Marc Garnier, Lise Morer, Tiphaine Goletto, Justine Frija-Masson, Paul-Henri Wicky, Pierre Jaquet, Catherine Bancal, Margarita Hurtado-Nedelec, Luc de Chaisemartin, Madeleine Jaillet, Arnaud…

Montefiore-Einstein Researchers Test Whether Molnupiravir Can Prevent COVID-19

As part of a recently launched international phase 3 clinical trial, Montefiore Health System and Albert Einstein College of Medicine are investigating whether the Merck antiviral pill, molnupiravir, now approved in Britain for treating COVID-19, can prevent COVID-19 in unvaccinated individuals living with people who have contracted the disease. Montefiore-Einstein is the first and only New York State site for the trial and was selected due to its diverse patient population and expertise in clinical trials of COVID-19 and other infectious diseases.

Study Observes Worse COVID-19 Vaccine Response in Patients Taking Glucocorticoids or B-Cell Therapies

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.

Fear of Side Effects, Including Rheumatic Disease Flares, Driving COVID-19 Vaccine Hesitancy Among Some Patients

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in Alabama, one in 10 racial or ethnic minority patients with a rheumatic disease in a large rheumatology clinic said they were unlikely to get vaccinated against COVID-19.

Ventilation Matters: Engineering Airflow to Avoid Spreading COVID-19

As we approach two full years of the COVID-19 pandemic, we now know it spreads primarily through airborne transmission. The virus rides inside tiny microscopic droplets or aerosol ejected from our mouths when we speak, shout, sing, cough, or sneeze. It then floats within the air, where it can be inhaled by and transmitted. This inspired researchers in India to explore how we can better understand and engineer airflow to mitigate the transmission of COVID-19.

Patients taking Rituximab Could Benefit from Third COVID-19 Vaccine Dose

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.

In Covid-19 Vaccinated People, Those with Prior Infection Likely to Have More Antibodies

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

Monoclonal antibody treatment highly effective at reducing COVID-19 hospitalizations

Researchers published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored by Vir Biotechnology and GlaxoSmithKline. The study found that compared to the placebo group, COVID-19 patients who received sotrovimab had a significantly reduced risk of hospitalization or death and that the treatment, which was administered by intravenous infusion on an outpatient basis, was safe.

Rutgers Expert Available to Discuss Mixing and Matching of COVID-19 Vaccines, Booster Shots

Rutgers infectious disease expert Shobha Swaminathan is available to discuss the mixing and matching of COVID-19 vaccines and boosters as the Food and Drugs Administration authorized booster shots for both the Johnson & Johnson and Moderna vaccines. “There is mounting…

AI Tool Pairs Protein Pathways with Clinical Side Effects, Patient Comorbidities to Suggest Targeted Covid-19 Treatments

Researchers led by Jeffrey Skolnick have designed a new AI-based “decision prioritization tool” that combines data on protein pathways with common Covid-19 side effects and known patient comorbidities. The tool offers possible targeted treatment options with existing FDA-approved drugs to foster better health outcomes for individuals fighting Covid-19.

Seniors Should Stay Fit, Body & Mind – Chula Suggests Ways to Exercise Safely at Home to Keep COVID-19 Away

Chula physical therapy specialist invites seniors to exercise to boost their immunity against COVID-19 and stay fit even during home quarantine with easy ways to exercise at home during the lockdown.

SCIENION and Pictor Limited Partner to Commercialize High-Throughput SARS-CoV-2 Antibody Testing System to Support Ongoing Fight Against Pandemic

Today SCIENION, a BICO company, announced it has entered into a strategic collaboration with diagnostic biotechnology company Pictor Limited to commercialize a high throughput SARS-CoV-2 antibody testing system. In the collaboration, the two companies will incorporate SCIENION’s CL2 sciREADER system into the PictArray SARS-CoV-2 Serology Test to create the only platform capable of testing both anti-nucleocapsid and anti-spike antibodies in one reaction. This analysis will be key to support the sustained fight against the pandemic by measuring the population’s level of herd immunity through natural infections and vaccinations.

“Read Medicine Labels” – How to Safely Use Green Chiretta Against COVID-19

Chula Pharmaceutical Science urges consumers to pay attention to “medicine labels” to choose and use green chiretta (Andrographis paniculata) effectively and safely. They also cautioned that the government should modify the labels, and control the price of herbal medicines that help in curbing the current pandemic.

Rutgers Global Health Expert Available to Discuss the Global Need for More COVID-19 Vaccines

Rutgers global health expert Richard Marlink, M.D., is available to discuss the importance of prioritizing vaccinations in low- to middle-income countries that need it the most, following President Biden’s pledge to donate an additional 500 million doses of the Pfizer-BioNTech COVID-19…